“…Sienna Biopharmaceuticals, Inc. (SNNA) (the “Company”), a clinical-stage biopharmaceutical company, today announced that, on November 12, 2019, the Nasdaq Hearings Panel (the “Panel”) granted the Company’s request for continued listing on the Nasdaq Stock Market (“Nasdaq”), subject to certain conditions…” https://finance.yahoo.com/news/sienna-biopharmaceuticals-announces-successful-appeal-133000812.html… Continue Reading…